DLF Science Advisory Board Spotlight
Dan Lewis Foundation | Summer 2024

Stephen Mark Strittmatter, MD, PhD, earned his undergraduate degree from Harvard, and completed doctoral training at Johns Hopkins. His medical internship and neurology residency were at Massachusetts General Hospital. He joined the Yale faculty in 1993, and is now Chair and Professor of Neuroscience and Vincent Coates Professor of Neurology.  He is Director of the Kavli Institute for Neuroscience at Yale, the Yale Cellular Neuroscience, Neurodegeneration and Repair Program, the Yale Alzheimer Disease Research Center and the Yale Memory Disorders Clinic.


His work on developmental axonal guidance led to his discovery of a Nogo Receptor pathway critical for axonal re-growth after injury.  He showed that glia-derived inhibitors bind this receptor, activate RhoA and prevent neural repair.  He developed a soluble Nogo Receptor decoy protein that blocks the endogenous ligand-receptor interaction, promoting recovery from spinal cord injury and stroke. This therapeutic protein is now in clinical trials for patients with chronic spinal cord injury. Strittmatter has also translated discoveries in neurodegeneration to clinical approaches. Using innovative screens, he identified the roles of Prion Protein and metabotropic glutamate receptor 5 (mGluR5) as Aß oligomer receptors. He linked activation of these receptors to a pair of synaptic tyrosine kinases, the Tau-interacting Fyn and the AD risk gene PTK2B. Critically, this pathway contributes to synapse loss and memory deficits in preclinical models.  He subsequently identified a Fyn inhibitor which was tested in an AD clinical trial.  Strittmatter has developed additional methods for targeting this pathway with robust preclinical efficacy.  One approach uses novel mGluR5 silent allosteric modulators, which are now in clinical trials.


An author of over 280 original reports, Dr. Strittmatter has been recognized by the King Faisal International Prize in Medicine, Ameritec Award for Spinal Injury Research, McKnight Brain and Memory Disorders Award, Alzheimer Association Zenith Fellow Award, Senator Jacob Javits Award in the Neurosciences, and an NINDS Outstanding Investigator Award. 

The word arpah is written in blue letters on a white background.
By Dan Lewis Foundation July 31, 2025
On July 10, 2025, the Advanced Research Projects Agency for Health (ARPA-H) announced a major initiative titled Functional Repair of Neocortical Tissue or FRONT. The announcement states “FRONT will pioneer a curative therapy for the more than 20 million adults in the US living with chronic neocortical brain damage from neurodegeneration, stroke, trauma, and other causes, which costs the country an estimated $800 billion per year. Worldwide, more than 200 million people live with debilitating after-effects of brain damage.”  A set of informational meetings about this program and a due date for outlines of potential proposals have been set for August. Full proposals are due by September 25, 2025. Complete instructions, specifications, and expectations are delineated in the ARPA-H FRONT announcement. The FRONT announcement includes a clear expectation that the successful brain regeneration methods that are discovered will be used in clinical trials with persons with brain injury by the fifth year of the program. The DLF lauds ARPA-H for initiating this program. We are discussing possibilities for playing a supportive role as proposals develop. This exciting program is congruent with the original overarching goals of the DLF and confirms the validity of its mission.
Photo of Dr. Justin Burrell
By Dan Lewis Foundation July 31, 2025
Dr. Burrell is a translational neuroengineer in the Departments of Neurosurgery and Oral & Maxillofacial Surgery at the University of Pennsylvania. His research integrates advanced neural repair strategies with clinical translation, focusing on axon protection, nerve fusion, and engineered neural tissue for neurotrauma recovery. Dr. Burrell has led the development of multiple first-in-field innovations—including the first large-animal model of nerve fusion, delayed axonal fusion protocols, and the first orally active axonal protectants—positioning him as a recognized leader in regenerative neurotechnologies. He is co-founder of Neurostorative LLC and plays a central role in several other platforms aimed at neural reconnection, long-term preservation, and bio-integrated prosthetic systems.